India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment
Feb 12 (Reuters) - India's Zydus Lifesciences ZYDU.NS said on Thursday that it and its U.S. unit have agreed to pay $120 million to Astellas Pharma 4503.T as part of a deal to settle a patent dispute over the Japanese drugmaker's bladder disorder drug Mirabegron. Zydus and its unit will also pay a pre-paid per‑unit licensing fee on sales of its generic Mirabegron in the U.S. from the date of the agreement until September 2027, the company said. (Reporting by Hritam Mukherjee in Bengaluru; Editing by Sherry Jacob-Phillips) ((mailto: hritam.mukherjee@thomsonreuters.com; @MukherjeeHritam;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka